SCHEMBL7192452

SCHEMBL7192452

CCCC[Si](c1ccccc1)(c1ccccc1)[C@@]1(n2cc(CC)c(=O)[nH]c2=O)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TK2 O00142 3/20 0.35
TK1 P04183 1/20 0.35
ASAH1 Q13510 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4949384 0.91 TK2 (0.39) TK2TK1
SCHEMBL6851558 0.83 TK1 (0.34) TK2TK1
SCHEMBL3300455 0.75 RNASE1 (0.37) TK2TK1
SCHEMBL5668664 0.72 TK1 (0.39) TK2TK1
SCHEMBL9545108 0.72 TK2 (0.40) TK2TK1
SCHEMBL3458558 0.71 SLC28A1 (0.41)
SCHEMBL8539644 0.69 LMNA (0.37) TK2
SCHEMBL8815300 0.69 SLC5A1 (0.34)
SCHEMBL9029503 0.67 P2RY2 (0.41)
SCHEMBL9030188 0.67 P2RY2 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346065-A2 ANTISENSE MODULATION OF SRC-2 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2003-09-24 EP disclosed
WO-2003052072-A2 ANTISENSE MODULATION OF ESTROGEN RECEPTOR ALPHA EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2003-06-26 WO disclosed
WO-2003027327-A1 ANTISENSE MODULATION OF INTERLEUKIN 8 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2003-04-03 WO disclosed
WO-2002057409-A2 ANTISENSE MODULATION OF SRC-2 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2002-07-25 WO disclosed
WO-2001052864-A1 ANTISENSE MODULATION OF COT ONCOGENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed